Preclinical antitumour activity of F 11782, a novel dual catalytic inhibitor of topoisomerases
2000
Preclinical Study of F 11782, a New Cancer Drug
publication
Evidence: high
Author Information
Author(s): Kruczynski A, Etiévant C, Perrin D, Imbert T, Colpaert F, Hill B T
Primary Institution: Centre de Recherche Pierre Fabre
Hypothesis
This study aimed to define the anticancer efficacy of F 11782 against various tumor models.
Conclusion
F 11782 showed significant antitumor activity in multiple cancer models, outperforming existing treatments.
Supporting Evidence
- F 11782 increased survival in P388 leukaemia by 143–457%.
- F 11782 significantly increased survival in B16 melanoma and inhibited tumor growth.
- F 11782 inhibited pulmonary metastatic foci of B16F10 melanoma by 99%.
- F 11782 showed major inhibitory activity against MX-1 breast tumors.
- F 11782 caused tumor regressions in human tumor xenografts, unlike etoposide.
- F 11782 demonstrated good overall tolerance across multiple dose levels.
Takeaway
F 11782 is a new drug that helps fight cancer and works better than some older drugs in tests.
Methodology
The study tested F 11782 in various murine and human tumor models to assess its anticancer efficacy.
Statistical Information
P-Value
<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website